Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

419 Results

Document

HCP_Should-my-patients-start-on-a-biosimilar_FR.pdf

Nov 2022

Document

HCP_Should-I-switch-a-patient-to-a-biosimilar_FR.pdf

Nov 2022

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2022

Status: Current
ID: PET 2022-1

Jan 2023

Document

EsophagealCancerPreventionandEarlyDetectionPathway.pdf

Jan 2023

Document

EsophagealCancerDiagnosisPathway.pdf

Jan 2023

Document

EsophagealCancerFollow-upCarePathway.pdf

Jan 2023

Document

EsophagealCancerTreatmentPathway.pdf

Jan 2023

High Cost Therapy Funding Program

The High Cost Therapy Funding Program primarily funds high-cost injectable or oral cancer drugs given in inpatient units of the hospital. The...

Document

HCTFP_Policy_EN.pdf

Apr 2023

Document

HCTFP_Policy_Fr.pdf

Apr 2023

Drug

enfortumab vedotin

Other Name(s): Padcev®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Aug 2025

High Risk Ontario Breast Screening Program FAQs for Healthcare Providers

Les fournisseurs de soins primaires sont le premier point de contact pour les femmes, les personnes trans et les personnes non binaires qui peuvent...

Pages